IntelGenx's Robust Product Pipeline Addresses Significant Market Opportunities

Partner Formulation
Clinical Filing   Launch
Pipeline versa lagrge flec Migraine - RIZAPORT®
 exeltis logo 
intro logo2
flec Erectile Dysfunction - EXORDIA®
aquestive logo 
flec Schizophrenia
flec Neurodegenerative Brain Diseases
flec Opioid Dependence
(Buprenorphine / Naloxone)
 Endo 2018
flec Undisclosed  Endo 2018
flec Chronic Pain
iromed logo 
flec CBD  tilray
flec N, N-Dimethyltryptamine Screen Shot 2020 08 21 at 1.00.53 PM
flec Salvinorin A logo atai

Pipeline Disclaimer

The information included on this site reflects IntelGenx Corp. clinical development pipeline and is not intended for promotional purposes. It includes new indications or line extensions of currently approved products that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued or delayed, or to fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of August 25, 2020. IntelGenx assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.